New opportunities in the diagnosis and treatment of overactive bladder and urgent urinary incontinence according to the updated clinical guidelines on urinary incontinence (2024)

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The main changes and additions to the clinical guidelines "Urinary Incontinence" (2024) are presented in the review. Certain changes to the guidelines "Urinary Incontinence" developed by the Russian Society of Urologists (RSU) and approved by the Ministry of Health of the Russia became possible thanks to the work of the expert Councils, which include the national leading specialists dealing with the problem of urination disorders. The inclusion of the Russian drug in the clinical guidelines will allow regulating the prescription of bladder polypeptides (Vesusten) in the routine clinical practice of a urologist and will help a wider range of patients receive pathogenetic therapy for OAB/urgent urinary incontinence.

Full Text

Restricted Access

About the authors

Zaida K. Gadzhieva

FGAOU VO I.M. Sechenov First Moscow State Medical University

Author for correspondence.
Email: gadzhieva_z_k@staff.sechenov.ru
ORCID iD: 0009-0004-5442-1334

Ph.D., MD, Head of the Department of analysis of personnel policy, educational programs and scientific research of the National Medical Research Center for «Urology»

Russian Federation, Bolshaya Pirogovskaya str., 2, building 1. Moscow, 119991

References

  1. Order of the Ministry of Health of the Russian Federation No. 103n dated February 28, 2019 «On approval of the procedure and terms for the development of clinical guidelines, their revision, the standard form of clinical guidelines and requirements for their structure, composition and scientific validity of the information included in clinical guidelines» (clause 10 of the procedure and terms for the development of clinical guidelines, their revision). Russian (Приказ Минздрава России № 103н от 28.02.2019 «Об утверждении порядка и сроков разработки клинических рекомендаций, их пересмотра, типовой формы клинических рекомендаций и требований к их структуре, составу и научной обоснованности включаемой в клинические рекомендации информации» (п. 10 порядка и сроков разработки клинических рекомендаций, их пересмотра)).
  2. Clinical guidelines «Urinary incontinence» https://cr.minzdrav.gov.ru/view-cr/8_2. Russian (Клинические рекомендации «Недержание мочи» https://cr.minzdrav.gov.ru/view-cr/8_2).
  3. Resolution of the Expert Council on Urodynamics and Neurourology of the Neurourology Section of the Russian Society of Urologists (ROU). Urologiia. 2022; 6: 134–136.Harding C. et al. EAU Guidelines on Management of Non-Neurogenic Female Lower Urinary Tract Symptoms, 2023. Russian (Резолюция Экспертного Совета по Уродинамике и Нейроурологии секции Нейроурологии Российского Общества Урологов (РОУ). Урология. 2022;6:134–136).
  4. Harding C. et al. EAU Guidelines on Management of Non-Neurogenic Female Lower Urinary Tract Symptoms, 2023.
  5. Pushkar D.Y.U., Kupriyanov Y.A., GAMIDOV S.I., Krivoborodov G.G., Spivak L.G., Al-Shukri S.K.H., Lerman D.M., Gomberg V.G., Bogdan E.N., Shchukin V.L., Chibirov K.H., Gelashvili V.V., Gural A.K., Keshishchev N.G., Staroselskaia M.A., Bastrikova N.A. Afety and efficacy of Vesusten® for patients with overactive bladder. Urologiia. 2022;3:42–51. doi: 10.18565/urology.2022.3.42-51. Russian (Д.Ю. Пушкарь, Ю.А. Куприянов, С.И. Гамидов, Г.Г. Кривобородов, Л.Г. Спивак, С.Х. Аль-Шукри и др. Оценка безопасности и эффективности лекарственного препарата Везустен у пациентов с гиперактивным мочевым пузырем. Urologiia. 2022;3:42–51. doi: 10.18565/urology.2022.3.42-51).
  6. Green A. et al. Drugs Contributing to Anticholinergic Burden and Risk of Fall or Fall-Related Injury among Older Adults with Mild Cognitive Impairment, Dementia and Multiple Chronic Conditions: A Retrospective Cohort Study. Drugs Aging. 2019;36(3):289–297. doi: 10.1007/s40266-018-00630-z. PMID: 30652263; PMCID: PMC6386184
  7. Methodological guide of the Ministry of Health of the Russian Federation «Pharmacotherapy in elderly and senile persons», 2018. Russian (Методическое руководство Минздрава РФ «Фармакотерапия у лиц пожилого и старческого возраста», 2018).
  8. Wagg A. et al. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol. 2020 Feb;77(2):211-220. doi: 10.1016/j.eururo.2019.10.002. Epub 2019 Nov 13. PMID: 31733990;
  9. Blok B. et al. EAU Guidelines on Neuro-Urology, 2023; Tannenbaum, C., et al. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging. 2012;29:639. https://pubmed.ncbi.nlm.nih.gov/22812538/.
  10. Boustani M. et al. Impact of anticholinergics on the aging brain: A review and practical application. Aging Health. 2008; 4(3):311–320. doi: 10.2217/1745509X.4.3.311
  11. Urology. Russian clinical guidelines / edited by Yu.G. Alyaev, P.V. Glybochko, D.Yu. Pushkar. M., 2017. 544 p. Russian (Урология. Российские клинические рекомендации / под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. M., 2017. 544 с.).
  12. Harding C., et al. EAU Guidelines on Management of Non-Neurogenic Female Lower Urinary Tract Symptoms, 2023.
  13. Resolution of the Expert Council «Current prospects for pathogenetic therapy of overactive bladder syndrome/urinary incontinence. The first-year experience of using the drug Vesusten». Urologiia. 2023;5:136–138. DOI: https://dx.doi.org/10.18565/urology.2023.5.136-138. Russian (Резолюция экспертного совета «Перспективы патогенетической терапии гиперактивного мочевого пузыря/недержания мочи в современных реалиях. Первый год применения препарата Везустен». Урология. 2023;5:136–138. DOI: https://dx.doi.org/10.18565/urology.2023.5.136-138).
  14. Report on the research work on the topic «Studying the effect of Vesusten on the organotypic culture of various mouse tissues». St.-Petersburg. 2014. 13 p. Russian (Отчет о научно-исследовательской работе по теме «Изучение влияния Везустена на органотипическую культуру различных тканей мыши». СПб., 2014. 13 с.
  15. Report on the research work «Study of the effect of Vesusten on the smooth muscle cells of the detrusor of the bladder». St-Petersburg, 2017. 19c. Russian (Отчет о научно-исследовательской работе «Изучение влияния Везустена на гладко-мышечные клетки детрузора мочевого пузыря». СПб., 2017. 19 с.).
  16. Khavinson V.H., Anisimov V.N. 35-year experience in study of peptide regulation of aging. Advances in Gerontology. 2009;22(1):11–23. Russian (Хавинсон В.Х., Анисимов В.Н. 35-летний опыт исследований пептидной регуляции старения. Успехи геронтологии. 2009;22(1):11–23. Russian (Khavinson V.H., Anisimov V.N. 35-year experience in study of peptide regulation of aging. Advances in Gerontology. 2009;22(1):11–23).
  17. Clinical study report URO-VZS-01 dated August 20, 2018 [Clinical study report URO-VZS-01 dated August 20, 2018], RCT No. 654 dated December 14, 2017 No. URO-VZS-01 – GRLSBASE. Russian (Отчёт о клиническом исследовании URO-VZS-01 от 20 августа 2018 [Clinical study report URO-VZS-01 dated August 20, 2018], РКИ № 654 от 14.12.2017 № URO-VZS-01 - GRLSBASE).
  18. Clinical study report VST-10-2018 dated December 12, 2019 [Clinical study report VST-10-2018 dated December 12, 2019], RCT No. 165 dated 04/05/2019 VST-10-2018 – GRLSBASE. Russian (Отчёт о клиническом исследовании VST-10-2018 от 12 декабря 2019 г. [Clinical study report VST-10-2018 dated December 12, 2019], РКИ № 165 от 05.04.2019 VST-10-2018 - GRLSBASE).
  19. Abdallah Nemer M.N., Belousov I.I., Kogan M.I., Goncharova Z.A., Belousova M.E. Efficacy and safety of the polypeptide drug «Vesusten» in the correction of neurogenic LUTS in Multiple Sclerosis. Results of the pilot study. Urologiia. 2024;3:63–71 Doi: https://dx.doi.org/10.18565/urology.2024.3.63-71. Russian (Абдуллах Немер М.Н., Белоусов И.И., Коган М.И., Гончарова З.А., Белоусова М.Е. Эффективность полипептидного препарата «Везустен» в коррекции нейрогенных СНМП при рассеянном склерозе. Результаты пилотного исследования. Урология. 2024;3:63–71). Doi: https://dx.doi.org/10.18565/urology.2024.3.63-71.
  20. Al Afraa T. et al. Normal lower urinary tract assessment in women: I. Uroflowmetry and post-void residual, pad tests, and bladder diaries. Int Urogynecol J. 2012;23:681.
  21. Van Leijsen S.A. et al. Can preoperative urodynamic investigation be omitted in women with stress urinary incontinence? A non-inferiority randomized controlled trial. Neurourol Urodyn. 2012;31:1118;
  22. Bodmer N.S. et al. Randomised Controlled Trials Assessing the Clinical Value of Urodynamic Studies: A Systematic Review and Meta-analysis. European urology open science. 2022;44:131–141.
  23. Clement K.D., Lapitan M.C., Omar M.I., Glazener C.M. Urodynamic studies for management of urinary incontinence in children and adults. Cochrane Database Syst Rev. 2013;2013(10):CD003195. doi: 10.1002/14651858.CD003195.pub3. PMID: 24166676; PMCID: PMC6599826.
  24. Thiel D.D. et al. Do clinical or urodynamic parameters predict artificial urinary sphincter outcome in post-radical prostatectomy incontinence? Urology. 2007;69:315. https://www.ncbi.nlm.nih.gov/pubmed/17320671
  25. Order of the Ministry of Health of the Russian Federation No. 804n of October 13, 2017 (as amended on September 24, 2020). Russian (Приказ Минздрава РФ N804н от 13 октября 2017 года (с изменениями на 24 сентября 2020 г.).
  26. Clause 3 of Clause 1 of Article 37 of Federal Law No. 323-FZ of November 21, 2011 «On the Fundamentals of Protecting the Health of Citizens in the Russian Federation». Russaina (пп. 3 п. 1 ст. 37 Федерального закона № 323-ФЗ от 21.11.2011 «Об основах охраны здоровья граждан в Российской Федерации»).
  27. Rubricator of Clinical Recommendations. https://cr.minzdrav.gov.ru/develop-clinRec. Russian (Рубрикатор клинических рекомендаций. https://cr.minzdrav.gov.ru/develop-clinRec).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Bionika Media